[go: up one dir, main page]

WO2005065650A3 - Formulations - Google Patents

Formulations Download PDF

Info

Publication number
WO2005065650A3
WO2005065650A3 PCT/GB2004/004241 GB2004004241W WO2005065650A3 WO 2005065650 A3 WO2005065650 A3 WO 2005065650A3 GB 2004004241 W GB2004004241 W GB 2004004241W WO 2005065650 A3 WO2005065650 A3 WO 2005065650A3
Authority
WO
WIPO (PCT)
Prior art keywords
carboxylic acid
acid surfactant
aerosol formulations
surfactant
pharmaceutical formulations
Prior art date
Application number
PCT/GB2004/004241
Other languages
English (en)
Other versions
WO2005065650A2 (fr
Inventor
Craig Davies-Cutting
Tristan Fairbrother
Alexander J M Munro
Trevor Riley
Renata Zofia Williams
Original Assignee
Glaxo Group Ltd
Craig Davies-Cutting
Tristan Fairbrother
Alexander J M Munro
Trevor Riley
Renata Zofia Williams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Craig Davies-Cutting, Tristan Fairbrother, Alexander J M Munro, Trevor Riley, Renata Zofia Williams filed Critical Glaxo Group Ltd
Priority to JP2006530593A priority Critical patent/JP2007508283A/ja
Priority to EP04820961A priority patent/EP1684721A2/fr
Publication of WO2005065650A2 publication Critical patent/WO2005065650A2/fr
Publication of WO2005065650A3 publication Critical patent/WO2005065650A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne de nouvelles formulations pharmaceutiques de médicaments se présentant sous forme de particules, tels que des agonistes bêta et/ou des stéroïdes anti-inflammatoires dans des agents propulseurs d'hydrofluoroalcane comprenant un tensioactif d'acide carboxylique.
PCT/GB2004/004241 2003-10-09 2004-10-06 Formulations WO2005065650A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006530593A JP2007508283A (ja) 2003-10-09 2004-10-06 カルボン酸界面活性剤を含むエアロゾル製剤
EP04820961A EP1684721A2 (fr) 2003-10-09 2004-10-06 Formulations d'aerosol comprenant un tensio actif d'un acide carboxylique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0323701.3 2003-10-09
GBGB0323701.3A GB0323701D0 (en) 2003-10-09 2003-10-09 Formulations

Publications (2)

Publication Number Publication Date
WO2005065650A2 WO2005065650A2 (fr) 2005-07-21
WO2005065650A3 true WO2005065650A3 (fr) 2006-04-27

Family

ID=29433610

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004241 WO2005065650A2 (fr) 2003-10-09 2004-10-06 Formulations

Country Status (4)

Country Link
EP (1) EP1684721A2 (fr)
JP (1) JP2007508283A (fr)
GB (1) GB0323701D0 (fr)
WO (1) WO2005065650A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2013211E (pt) 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
NZ594157A (en) 2008-12-30 2013-07-26 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
WO2010150014A1 (fr) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (fr) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2678338B1 (fr) 2011-02-25 2015-09-09 Novartis AG Composés et compositions en tant qu'inhibiteurs de trk

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012265A1 (fr) * 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYLE) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYLE-3-OXO-ANDROST-1,4,-DIENE-17-ACIDE CARBOTHIOIQUE S-FLUOROMETHYLE ESTER UTILISE COMME AGENT ANTI INFLAMMATOIRE
WO2002066422A1 (fr) * 2001-02-14 2002-08-29 Glaxo Group Limited Derives de phenethanolamine pour le traitement de maladies respiratoires
WO2003013610A2 (fr) * 2001-08-03 2003-02-20 Glaxo Group Limited Composes d'agents de surface et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012265A1 (fr) * 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYLE) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYLE-3-OXO-ANDROST-1,4,-DIENE-17-ACIDE CARBOTHIOIQUE S-FLUOROMETHYLE ESTER UTILISE COMME AGENT ANTI INFLAMMATOIRE
WO2002066422A1 (fr) * 2001-02-14 2002-08-29 Glaxo Group Limited Derives de phenethanolamine pour le traitement de maladies respiratoires
WO2003013610A2 (fr) * 2001-08-03 2003-02-20 Glaxo Group Limited Composes d'agents de surface et leurs utilisations

Also Published As

Publication number Publication date
GB0323701D0 (en) 2003-11-12
WO2005065650A2 (fr) 2005-07-21
JP2007508283A (ja) 2007-04-05
EP1684721A2 (fr) 2006-08-02

Similar Documents

Publication Publication Date Title
WO2005065650A3 (fr) Formulations
AU2206801A (en) Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
AU2003213020A1 (en) Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1219293A3 (fr) Composition d' aérosol pharmaceutique
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
WO2005063231A3 (fr) Formulation contenant un acide carboxylique ou un ester de celui-ci
WO2003030818A3 (fr) Principes actifs vehicules par des perles de liposomes
IL160253A0 (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
IL173726A (en) Pharmaceutical compositions containing n-n-dihaloamino acids and their uses
CA2416403A1 (fr) Formulation medicinale d'aerosol
ATE342053T1 (de) Formulierungen zur inhalation
BR9809448A (pt) Produtos aerossóis medicinais.
TNSN04148A1 (en) Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
WO2007014124A3 (fr) Formes posologiques et preparations a charge medicamenteuse elevee
WO2004047792A3 (fr) Glucocorticoides liposomaux
CA2317999A1 (fr) Formulation pharmaceutique de propionate de fluticasone
AU2001278821A1 (en) Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
IL174336A0 (en) Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
WO2005011614A8 (fr) Combinaison de deshydroepiandrosterone ou de sulfate de deshydroepiandrosterone avec un anticorps anti-ige pour le traitement de l'asthme ou de la bronchopneumopathie obstructive chronique
WO2003066597A3 (fr) Composes guanidino
MXPA03001752A (es) Uso de la combinacion de salmeterol y propionato de fluticasona.
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
AU2001240674A1 (en) Dihydropyrimidine-5-carboxylic acid esters and use thereof as medicaments against viral diseases
WO2002059147A3 (fr) Peptides armes
WO2007008427A3 (fr) Compositions aerosol et procedes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006530593

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004820961

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004820961

Country of ref document: EP